玖玖资源网站,爆乳久久久,日韩精品乱码久久久蜜桃,精品呦国产一区二区三区,国产伦高清一区二区三区,sese一区二区,午夜精品福利一区二区三区,三级黄色网站久久免费

產(chǎn)品中心

Product center

CH5132799 ≥97%

CH5132799

源葉(MedMol)
S80011
1007207-67-1
C15H19N7O3S
377.42
品牌 貨號 產(chǎn)品規(guī)格 價格(RMB) 庫存(上海) 北京 武漢 南京 購買數(shù)量
源葉(MedMol) S80011-1mg ≥97% ¥236.00元 5 - - -
源葉(MedMol) S80011-5mg ≥97% ¥344.00元 5 - - -
源葉(MedMol) S80011-10mg ≥97% ¥550.00元 5 - - -
源葉(MedMol) S80011-25mg ≥97% ¥868.00元 6 - - -
源葉(MedMol) S80011-50mg ≥97% ¥1389.00元 5 - - -
源葉(MedMol) S80011-100mg ≥97% ¥2222.00元 3 - - -
產(chǎn)品介紹 參考文獻 質(zhì)檢證書(COA) 摩爾濃度計算器 相關產(chǎn)品

產(chǎn)品介紹

Izorlisib (CH5132799) is a selective class I PI3K inhibitor. Izorlisib inhibits class I PI3Ks, particularly PI3Kα, with an IC50 of 14 nM.
產(chǎn)品描述: Izorlisib (CH5132799) is a selective class I PI3K inhibitor. Izorlisib inhibits class I PI3Ks, particularly PI3Kα, with an IC50 of 14 nM.
靶點: PI3Kα:14 nM (IC50);PI3Kα-H1047R:5.6 nM (IC50);PI3Kα-E545K:6.7 nM (IC50);PI3Kα-E542K:6.7 nM (IC50);PI3Kγ:36 nM (IC50);PI3Kβ:120 nM (IC50);PI3Kδ:500 nM (IC50);PI3KC2β:5.3 μM (IC50);mTOR:1.6 μM (IC50);PI3K;mTOR
體內(nèi)研究:
Mice bearing BT-474 tumors (n=14) are orally administered 50 mg/kg of Everolimus on a daily basis for 31 days and then randomized. After randomization, the mice are orally administered 50 mg/kg of Everolimus (n=4) and 12.5 mg/kg (n=5), and 25 mg/kg (n=5) of Izorlisib on a daily basis for 7 days. C, the vehicle-, Everolimus, and CH5132799-treated (25 mg/kg) tumors are resected at 4 hours after terminal administration in B, lysed, and analyzed by Western blotting. Izorlisib administration leads to a remarkable regression in a dose-dependent manner of the tumors regrown after the long-term Everolimus treatment. The tumors are resected at the end of treatment and analyzed by Western blotting with respect to PI3K pathway inhibition. Izorlisib suppresses various effectors in the PI3K pathway, including Akt, FoxO1, S6K, S6, and 4E-BP1, whereas Everolimus inhibits only phosphorylation of S6K and S6, both downstream effectors of mTORC1
參考文獻:
1. Tanaka H, et al. The selective class I PI3K inhibitor CH5132799 targets human cancers harboring oncogenic PIK3CA mutations. Clin Cancer Res, 2011, 17(10), 3272-3281. 2. Ohwada J, et al. Discovery and biological activity of a novel class I PI3K inhibitor, CH5132799. Bioorg Med Chem Leff, 2011, 21(6), 1767-1772.
溶解性: Soluble  in  DMSO
保存條件: -20℃
配置溶液濃度參考:
1mg 5mg 10mg
1 mM 2.65 ml 13.248 ml 26.496 ml
5 mM 0.53 ml 2.65 ml 5.299 ml
10 mM 0.265 ml 1.325 ml 2.65 ml
50 mM 0.053 ml 0.265 ml 0.53 ml
注意: 部分產(chǎn)品我司僅能提供部分信息,我司不保證所提供信息的權(quán)威性,僅供客戶參考交流研究之用。

參考文獻

質(zhì)檢證書(COA)

如何獲取質(zhì)檢證書(COA)?
請輸入貨號和一個與之匹配的批號。
例如:
批號:C10000001 貨號:A800001-25g
在貨品標簽上如何找到貨號和批號?

摩爾濃度計算器

質(zhì)量 (mg) = 濃度 (mM) x 體積 (mL) x 分子摩爾量 (g/mol)

=
×
×

相關產(chǎn)品

主站蜘蛛池模板: 舒兰市| 文化| 镇安县| 平和县| 微山县| 西乡县| 离岛区| 苍山县| 政和县| 紫金县| 株洲县| 游戏| 江华| 清流县| 新野县| 日喀则市| 乐安县| 赫章县| 沐川县| 南华县| 洱源县| 临泉县| 海阳市| 正宁县| 墨竹工卡县| 临夏县| 光泽县| 安塞县| 宁都县| 体育| 新建县| 易门县| 长白| 阜城县| 东山县| 溧水县| 临城县| 南郑县| 射阳县| 高雄市| 松滋市|